Abstract
In this review we present recent studies on the effects of the protein phosphatase inhibitor microcystin on mammalian cells. Whereas high concentrations of microcystin promote liver cell death induced by ROS signalling without the involvement of typical apoptotic proteins, intermediate doses activate classic apoptotic pathways. Low concentrations however, increase liver cell survival and proliferation, and can cause primary liver cancer.
Keywords: Microcystin, protein phosphatases, PP1, PP2A, reactive oxygen species, cancer, apoptosis, mitochondria
Mini-Reviews in Medicinal Chemistry
Title: Microcystin Produces Disparate Effects on Liver Cells in a Dose Dependent Manner
Volume: 6 Issue: 3
Author(s): Lars Herfindal and Frode Selheim
Affiliation:
Keywords: Microcystin, protein phosphatases, PP1, PP2A, reactive oxygen species, cancer, apoptosis, mitochondria
Abstract: In this review we present recent studies on the effects of the protein phosphatase inhibitor microcystin on mammalian cells. Whereas high concentrations of microcystin promote liver cell death induced by ROS signalling without the involvement of typical apoptotic proteins, intermediate doses activate classic apoptotic pathways. Low concentrations however, increase liver cell survival and proliferation, and can cause primary liver cancer.
Export Options
About this article
Cite this article as:
Herfindal Lars and Selheim Frode, Microcystin Produces Disparate Effects on Liver Cells in a Dose Dependent Manner, Mini-Reviews in Medicinal Chemistry 2006; 6 (3) . https://dx.doi.org/10.2174/138955706776073475
DOI https://dx.doi.org/10.2174/138955706776073475 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Salinomycin Suppresses Tumorigenicity of Liver Cancer Stem Cells and Wnt/Beta-catenin Signaling
Current Stem Cell Research & Therapy Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics miR-203 Suppresses the Proliferation and Metastasis of Hepatocellular Carcinoma by Targeting Oncogene ADAM9 and Oncogenic Long Non-coding RNA HULC
Anti-Cancer Agents in Medicinal Chemistry Synthesis, In Vitro Biological Screening and Molecular Docking Studies of Novel Camphor-Based Thiazoles
Medicinal Chemistry Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Application of Gene Therapy in Diabetes Care
Infectious Disorders - Drug Targets Natural Products as a Source of Protein Kinase Activators and Inhibitors
Current Topics in Medicinal Chemistry IP6 in Cancer Therapy: Past, Present and Future
Current Cancer Therapy Reviews Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Biomedical Imaging in Implantable Drug Delivery Systems
Current Drug Targets Optical Image-Guided Cancer Therapy
Current Pharmaceutical Biotechnology Ursolic and Oleanolic Acids as Potential Anticancer Agents Acting in the Gastrointestinal Tract
Mini-Reviews in Organic Chemistry Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Current Cancer Drug Targets Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics